How Uloric (febuxostat) lowers uric acid
Uloric’s mechanism is enzyme inhibition. It blocks xanthine oxidase, the key enzyme that converts purines into uric acid during the final steps of uric acid production. By inhibiting xanthine oxidase, Uloric reduces the body’s uric acid formation, which helps lower serum urate levels.
What xanthine oxidase normally does
In purine metabolism, xanthine oxidase catalyzes oxidation steps that end with uric acid. When xanthine oxidase is inhibited, less xanthine is converted onward to uric acid, so urate production falls.
Why that matters for gout and hyperuricemia
Lower serum urate reduces the likelihood that monosodium urate crystals will form and deposit in joints and tissues. Over time, that helps manage hyperuricemia associated with gout and can reduce flares as urate levels stabilize.
Is Uloric the same type of drug as allopurinol?
Both Uloric (febuxostat) and allopurinol act by inhibiting xanthine oxidase, but they are different molecules. Their shared target is what drives their overlapping effect: lowering uric acid by reducing production.
Where to verify patents and exclusivity (if you’re researching the product)
If your goal is to connect the drug’s mechanism to its regulatory or market history, DrugPatentWatch.com tracks febuxostat patent and exclusivity details: https://www.drugpatentwatch.com/p/drug/febuxostat/